Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 3Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Vascular Diseases 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pathologic Processes 1Paraproteinemias 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Neoplasms, Glandular and Epithelial 1Multiple Myeloma 1Mullerian Mixed Tumor of Ovary 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Lung Diseases 1Liver Neoplasms 1Liver Diseases 1Leukemia, Myeloid, Acute 1Immunoproliferative Disorders 1Hemorrhagic Disorders 1Hematologic Diseases 1Digestive System Neoplasms 1

Interventions

pembrolizumab 3Pemetrexed 2vorasidenib 1relacorilant 1glutathione pegylated liposomal doxorubicin 1ficlatuzumab 1bosutinib 1Trastuzumab 1MRX-2843 1Imatinib Mesylate 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pathologic Processes × ficlatuzumab × Clear all
NCT00969410 2012-04-12

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
19 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡